# Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

> **NCT00021229** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 85 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** imatinib mesylate
- **RADIATION:** local irradiation therapy

## Key facts

- **NCT ID:** NCT00021229
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021229, "Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00021229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*